# Safety of Romiplostim (Nplate®) Following UCBT

> **NCT02046291** · PHASE1 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 21 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Romiplostim

## Key facts

- **NCT ID:** NCT02046291
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-10
- **Primary completion:** 2020-12-12
- **Final completion:** 2021-06-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02046291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02046291, "Safety of Romiplostim (Nplate®) Following UCBT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02046291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*